Ranitidine therapy for esophagitis in children with developmental disabilities

Area of Science:

• Pediatric Gastroenterology
• Neurology

Background:

• Esophagitis is a frequent complication in children diagnosed with cerebral palsy.
• Conventional doses of histamine2-receptor antagonists, like ranitidine, have demonstrated inconsistent efficacy in treating this condition.

Purpose of the Study:

• To evaluate the effectiveness of escalated doses of ranitidine in managing esophagitis in pediatric patients with cerebral palsy.
• To assess the utility of endoscopy and pH monitoring in guiding treatment and assessing response.

Main Methods:

• Children with cerebral palsy and esophagitis received higher-than-usual doses of ranitidine.
• Endoscopic examinations and 24-hour esophageal pH monitoring were employed to track treatment progress and patient response.
• Doses administered were approximately 9.3 mg/kg/day and 14.8 mg/kg/day.

Main Results:

• A dose of 9.3 mg/kg/day of ranitidine showed no significant improvement in visual or microscopic esophagitis after three months.
• A higher dose of 14.8 mg/kg/day led to minor microscopic healing but notably improved patient symptoms.
• No correlation was found between the initial esophageal reflux index and the severity of esophagitis or treatment outcomes.
• Ranitidine infrequently elevated gastric pH, indicating limited effectiveness in acid suppression.

Conclusions:

• Increased doses of ranitidine are not a reliable method for healing esophagitis in children with cerebral palsy.
• Esophageal pH monitoring is not a dependable tool for diagnosing reflux esophagitis in this specific patient group.
• The study highlights the limitations of ranitidine in managing refractory esophagitis in children with neurological impairments.